Be Aware Canagliflozin Might Increase Amputation Risk in Diabetes Patients

A new boxed warning about amputation with canagliflozin (Invokana, etc) will raise more questions about the safety of SGLT2 inhibitors.

This is the latest in a growing list of flozin concerns...ketoacidosis, acute kidney injury, UTIs, yeast infections, etc.

Amputations, mainly of the toe or mid-foot, are seen in about 6 in 1,000 patients taking canagliflozin per year...compared to about 3 in 1,000 patients per year on other diabetes meds.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals